

Results of Share Purchase Plan

[CardieX Limited](#) (ASX: CDX) (CardieX, the Company) is pleased to announce the successful completion of its Share Purchase Plan (SPP), which closed on 26 September 2022.

The Company received applications for fully paid ordinary shares (Shares) from eligible shareholders (which included Directors) under the SPP at an issue price of \$0.30 per share in the amount of \$1.593 million (before costs) representing a 59.3% over-subscription over the originally targeted raise of \$1.0 million.

As disclosed in the SPP Offer Booklet (refer ASX release 26 August 2022), the Company reserved the right to conduct either a scale-back of over-subscriptions above the targeted of \$1.0 million, or to accept over-subscriptions above the target. In response to the strong demand from shareholders, the Company has elected to accept the full \$1.593 million of valid applications including the \$593,000 in oversubscriptions and therefore not conduct any scale-back.

As previously announced, the Company intends for the funds raised under the SPP to be primarily used to support and accelerate new product initiatives related to the Company's CONNEQT subsidiary as well as corporate initiatives in the USA. CONNEQT is developing medical devices, digital solutions, and wearables for use by consumers, patients, clinicians, and other healthcare channels for the large and growing markets associated with home health, remote patient monitoring and decentralized clinical trials.

Proceeds from the SPP will also be used to provide additional working capital for the existing operations and to meet future regulatory requirements.

The Company expects allotment and issue of the SPP shares to occur on Thursday, 29 September 2022 as per the updated SPP timetable announced on 23 September 2022.

Niall Cairns, Executive Chairman of CardieX commented:

"We are very pleased with the support we have received from our shareholders under the SPP which is representative of the confidence that shareholders have in our growth plan and vision for the Company, despite the tough economic times. I would like to thank all our shareholders who have supported us through the SPP as we move towards our new product launches and other corporate activities."

Approved by the Board of Directors and Released by Jarrod White, Director.

For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

Investor Relations – USA

Matt Selinger

Managing Director, Integrous Communications

mselinger@integcom.com

About CardieX

CardieX is a global health technology company. Its [ATCOR](#) subsidiary is a world leader in medical devices for hypertension, cardiovascular disease, and other vascular health disorders based on the Company's "gold standard" SphygmoCor® central blood pressure technology. CardieX's [CONNEQT](#) subsidiary develops and markets medical devices, digital solutions, and wearables for home health, primary clinician, and other healthcare channels. CardieX is listed on the Australian Stock Exchange (ASX:CDX).